Drugs / Rabavert vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04882514 Comparator | Nov 2022 → May 2025 | streptococcal infection | University of Alberta | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabavert vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882514 ↗ |
| Modality | Vaccine | “The Rabavert vaccine will be used as a control comparator” NCT04882514 ↗ |
| Route | Intramuscular | “All vaccines will be administered intramuscularly” NCT04882514 ↗ |